Dual inhibition of CRD-BP and BRAF in BRAF-mutant Melanoma - A novel approach to overcome resistance to BRAF inhibitors

被引：0
|
作者：
Kim, T. [1 ,2 ]
Xu, Y. G. [1 ]
Setaluri, V. [1 ]
Spiegelman, V. [1 ,2 ]
机构：
[1] Univ Wisconsin, Dermatol, Madison, WI USA
[2] Univ Wisconsin, Mol & Environm Toxicol, Madison, WI USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
618
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] Resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma
    Patel, Hima
    Yacoub, Nour
    Garrett, Joan T.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB43 - AB43
  • [2] BRAF and MEK inhibitors in BRAF-mutant melanoma
    Sharma, Sharan Prakash
    [J]. LANCET ONCOLOGY, 2012, 13 (11): : E468 - E468
  • [3] Inhibition of BRAF and MEK in BRAF-mutant melanoma
    Smalley, Keiran S. M.
    Sondak, Vernon K.
    [J]. LANCET, 2015, 386 (9992): : 410 - 412
  • [4] Novel mechanisms of resistance in BRAF-mutant melanoma
    Poulikakos, Poulikos I.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [5] Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma
    Aya, F.
    Fernandez-Martinez, A.
    Gaba, L.
    Victoria, I.
    Tosca, M.
    Pineda, E.
    Gascon, P.
    Prat, A.
    Arance, A.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (01): : 119 - 124
  • [6] Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma
    F. Aya
    A. Fernandez-Martinez
    L. Gaba
    I. Victoria
    M. Tosca
    E. Pineda
    P. Gascon
    A. Prat
    A. Arance
    [J]. Clinical and Translational Oncology, 2017, 19 : 119 - 124
  • [7] BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma
    Paoluzzi, Luca
    Hanniford, Douglas
    Sokolova, Elena
    Osman, Iman
    Darvishian, Farbod
    Wang, Jinhua
    Bradner, James E.
    Hernando, Eva
    [J]. CANCER MEDICINE, 2016, 5 (06): : 1183 - 1193
  • [8] BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
    Bai, X.
    Mao, L. L.
    Chi, Z. H.
    Sheng, X. N.
    Gui, C. L.
    Kong, Y.
    Dai, J.
    Wang, X.
    Li, S. M.
    Tang, B. X.
    Lian, B.
    Zhou, L.
    Yan, X. Q.
    Guo, J.
    Si, L.
    [J]. NEOPLASMA, 2017, 64 (04) : 626 - 632
  • [9] Potential combinatorial strategies to overcome drug resistance in BRAF-mutant melanoma
    Dompe, Nicholas A.
    Lin, Eva
    Peng, Jing
    Chan, Grace
    Chan, Grace
    Chan, Grace
    Tien, Janet
    Merchant, Mark
    Bourgon, Richard
    Settleman, Jeffrey
    Wilson, Timothy
    Neve, Richard M.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21
  • [10] IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
    Patel, Hima
    Mishra, Rosalin
    Yacoub, Nour
    Alanazi, Samar
    Kilroy, Mary Kate
    Garrett, Joan T.
    [J]. CANCERS, 2021, 13 (22)
12345